BALPHARMA.NSBALPHARMA.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -10.42% | -13.47% | -11.41% | +0.45% | +19.87% |
| Gross Profit Growth | +1.35% | -12.30% | +80.15% | -4.52% | -42.22% |
| EBITDA Growth | +4.75% | -27.58% | -6.89% | -8.59% | +15.49% |
| Operating Income Growth | +4.99% | -26.58% | -12.33% | -33.72% | +24.49% |
| Net Income Growth | -45.87% | -0.72% | -22.58% | -31.90% | +269.89% |
| EPS Growth | -41.07% | +7.80% | -18.75% | -30.77% | +239.39% |
| EPS Diluted Growth | -41.07% | +7.80% | -18.75% | -30.77% | +239.39% |
| Weighted Average Shares Growth | -7.74% | -7.74% | -4.71% | -1.64% | +9.18% |
| Weighted Average Shares Diluted Growth | -7.74% | -7.74% | -4.71% | -1.64% | +9.18% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -25.60% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -90.48% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -10.26% | +0.00% | +3858.46% | +0.00% |
| Inventory Growth | +0.00% | +17.32% | +0.00% | +25.40% | +0.00% |
| Asset Growth | +0.00% | +5.06% | +0.00% | +2.91% | +0.00% |
| Book Value per Share Growth | +32.76% | +21.09% | +17.28% | +15.76% | +0.00% |
| Debt Growth | +0.00% | +5.74% | +0.00% | -0.05% | +0.00% |
| R&D Expense Growth | +0.00% | -44.64% | +0.00% | +0.00% | -100.00% |
| SG&A Expenses Growth | +27.20% | -5.50% | -100.00% | +0.00% | -9.71% |